Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
China’s National Medical Products Administration has granted conditional marketing approval to vebreltinib (APL-101; PBL-1001) for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping mutations
Experts offer concluding insights on unmet needs in NSCLC treatment and the future of patient care.
Specialists discuss unmet needs that continue to exist in treating patients with NSCLC despite advances in treatment, and how these impact patient outcomes.
The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer.
A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).